We use cookies and other technologies on this website to enhance your user experience.
By clicking any link on this page you are giving your consent to our Privacy Policy and Cookies Policy.

NeoMate Screenshots

About NeoMate

NeoMate helps neonatal staff deal with various difficult situations on NICU.

NeoMate helps neonatal staff to provide the best possible care for unwell babies in the hospital setting. The app offers drug, infusion and fluid calculations, concise checklists for common clinical problems, and quick reference information to guide acute neonatal intensive care.

NeoMate is based upon established guidelines used by the London Neonatal Transfer Service (NTS), an organisation that transfers unwell babies between neonatal units in London and the South East of England. By standardising the care given to babies, it is hoped that the app will improve safety by reducing variability of prescribing practices and local guidelines between different units.

What's New in the Latest Version 31

Last updated on Sep 29, 2023

New version of the app to update various sections.
- Updated dose of adrenaline to latest Resuscitation Council guidelines.
- Atropine dose adjusted to BNFc
- Max weight reduced from 7kg to 6kg
- BAPM guideline update to include infographic
- CFM guide working again
- Clinic growth charts: infants born at 37-42 weeks are now plotted at their precise age, and not at 40 weeks (as was previously recommended on paper charts)
- External links now working
- Various other minor bug fixes

Translation Loading...

Additional APP Information

Latest Version

Request NeoMate Update 31

Uploaded by

Nathy Oliveira

Requires Android

Android 5.1+

Show More
Languages
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Subscribed Successfully!
You're now subscribed to APKPure.
Subscribe to APKPure
Be the first to get access to the early release, news, and guides of the best Android games and apps.
No thanks
Sign Up
Success!
You're now subscribed to our newsletter.